Channels
All News
In Focus
Special
AI
Bioregnum
Biotech Voices
Cell/Gene Tx
China
Coronavirus
Deals
Diagnostics
Discovery
FDA+
Financing
Health Tech
Law
Letters to the Editor
Manufacturing
Marketing
Nikkei Biotechnology
Opinion
Outsourcing
Peer Review
People
Pharma
R&D
Startups
Weekly
Webinars
Biopharma Jobs
More
Work at Endpoints
Letter to Editors
Editorial Standards
IPO Tracker
Webinars
Events
Sponsored Posts
Advertise
Privacy Policy
Endpoints Merch
About Us
Help
SIGN UP
LOG IN
about the author
ENDPOINTS
editor@endpointsnews.com
author articles
Biohaven’s $230M offering; Plus, three new PIPEs
Last year
News Briefing
Intra-Cellular aims to raise $500M; Lilly’s Prevail cuts three partnered programs
Last year
News Briefing
Takeda’s new deal with Kumquat; IL-2 biotech raises $55M
Last year
News Briefing
Mustang Bio to lay off workers; MaaT's new data for microbiome therapy
Last year
News Briefing
Japanese pharmaceutical regulations under review to resolve drug shortages and ensure stable supply
Last year
Nikkei Biotechnology
Nurix's $175M offering; Invivyd CEO is out
Last year
News Briefing
Century Therapeutics buys Clade; Eliem announces $120M PIPE and a deal
Last year
News Briefing
Skye Bioscience uplists; OncoX's licensing deal with ABVC BioPharma
Last year
News Briefing
Acrivon draws in $130M; Vincerx Pharma's Ph1 metastatic tumor data
Last year
News Briefing
LIB details Ph3 PCSK9 inhibitor data; Eyenovia seeks 'strategic alternatives'
Last year
News Briefing
Protara's $45M placement; Plus, news about Eupraxia and GenSight
Last year
News Briefing
Ascletis Pharma scraps liver disease program; Another reverse merger
Last year
News Briefing
Zymeworks removes CFO; Gilead extends Nurix deal
Last year
News Briefing
Bayer to cut 90 workers; Avalo's up to $185M private placement
Last year
News Briefing
Gamida Cell to go private; Stoke aims to raise $75M
Last year
News Briefing
Edgewood's $20M Series A; Nanoscope to pursue FDA approval for eye gene therapy later this year
Last year
News Briefing
Axsome clears Phase 3 in narcolepsy; Nkarta eyes $240M raise
Last year
News Briefing
Intellia exits hemophilia B pact with Regeneron; Sangamo targets $24M raise
Last year
News Briefing
Meiji Seika Pharma to supply Japan with self-amplifying mRNA Covid-19 vaccine in fall/winter of 2024
Last year
Nikkei Biotechnology
Innate ends Ph1b in peripheral T cell lymphoma; Layoffs at NextCure
Last year
News Briefing
Madrigal's $600M offering; PureTech to return $100M to shareholders
Last year
News Briefing
Bluebird's $175M loan; Spyre reveals second private placement
Last year
News Briefing
OcuTerra’s diabetic retinopathy drug fails PhII; Better Therapeutics to shut down
Last year
News Briefing
Regulus raises $100M; Cancer company files to go public
Last year
News Briefing
First page
Previous page
8
9
10
11
12
13
14
Next page
Last page